Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.64 |
| ▸ | F10 | P00742 | 14/20 | 0.64 |
| ▸ | PLAT | P00750 | 11/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 11/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 11/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929885 | 0.78 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6929744 | 0.78 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6929425 | 0.77 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6932081 | 0.77 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6930543 | 0.77 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL8276415 | 0.76 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6925618 | 0.71 | F2 (0.75) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6932738 | 0.69 | F2 (0.70) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6931386 | 0.69 | F2 (1.00) | F2F10PLATPRSS1PRSS2 | |
| SCHEMBL6929662 | 0.66 | F2 (0.73) | F2F10PLATPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | claimed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225131-A1 | Thrombin inhibitors | TFPI, SERPINC1, PLAT | F2 5/4885F10 27/4885PLAT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.